ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
An Overview of the Research Advancements in Bispecific Antibodies
August 30, 2023According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons. -
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
September 28, 2021Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab...
Pharma Sources Insight January 2025
